The cGAS-STING pathway drives neuroinflammation in ALS through aberrant recognition of cytoplasmic mitochondrial DNA released following TDP-43 pathology. Rather than targeting the downstream effector STING, therapeutic intervention at the upstream sensor cGAS (MB21D1) offers a more proximal approach to pathway inhibition. cGAS contains a distinct N-terminal DNA-binding domain and C-terminal nucleotidyltransferase catalytic domain connected by a flexible linker region. Upon mtDNA binding, cGAS un
The cGAS-STING pathway drives neuroinflammation in ALS through aberrant cytoplasmic mitochondrial DNA recognition, but therapeutic intervention may be more effectively achieved by targeting the downstream kinase TBK1 rather than STING itself. Following STING activation by cGAMP, the pathway's inflammatory output critically depends on TBK1 (TANK-binding kinase 1), a 729-amino acid serine/threonine kinase that serves as the obligate signal transducer for both type I interferon and pro-inflammatory
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammationneuroinflammation
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
7/11
dimensions won
cGAS Inhibitors for ALS Therapeutics: Ta
8/11
dimensions won
TBK1 Inhibitors as ALS Therapeutics: Tar
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.72
Evidence
0.00
0.33
Novelty
0.00
0.00
Feasibility
0.00
0.00
Impact
0.00
0.00
Druggability
0.85
0.85
Safety
0.58
0.58
Competition
0.70
0.70
Data
0.72
0.72
Reproducible
0.75
0.75
KG Connect
0.50
0.50
Score Breakdown
Dimension
cGAS Inhibitors for ALS Therap
TBK1 Inhibitors as ALS Therape
Mechanistic
0.720
0.720
Evidence
0.000
0.325
Novelty
0.000
0.000
Feasibility
0.000
0.000
Impact
0.000
0.000
Druggability
0.850
0.850
Safety
0.580
0.580
Competition
0.700
0.700
Data
0.720
0.720
Reproducible
0.750
0.750
KG Connect
0.500
0.500
Evidence
cGAS Inhibitors for ALS Therapeutics: Targeting Upstream mtD
No evidence citations yet
TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream ST
No evidence citations yet
Debate Excerpts
cGAS Inhibitors for ALS Therapeutics: Targeting Up
4 rounds · quality: 0.73
Theorist
# Therapeutic Hypotheses: TDP-43/cGAS/STING in Neurodegeneration
## Hypothesis 1: Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling...
Skeptic
# Critical Evaluation of TDP-43/cGAS/STING Hypotheses in Neurodegeneration
---
## Hypothesis 1: Chronic cGAS/STING Hyperactivation via Sustained Type I IFN Signaling
### Weak Links
- **Unproven chr...
Domain Expert
# Feasibility Assessment: TDP-43/cGAS/STING Therapeutic Hypotheses in Neurodegeneration
## Executive Summary
The source paper (Yu et al., Cell 2020) establishes a credible mechanistic link between T...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "STING Antagonists as ALS Therapeutics: Drug Repurposing",
"description": "Existing STING antagonists (H-151, SN-011, Compound 18) developed for a...
TBK1 Inhibitors as ALS Therapeutics: Targeting Dow
4 rounds · quality: 0.73
Theorist
# Therapeutic Hypotheses: TDP-43/cGAS/STING in Neurodegeneration
## Hypothesis 1: Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling...
Skeptic
# Critical Evaluation of TDP-43/cGAS/STING Hypotheses in Neurodegeneration
---
## Hypothesis 1: Chronic cGAS/STING Hyperactivation via Sustained Type I IFN Signaling
### Weak Links
- **Unproven chr...
Domain Expert
# Feasibility Assessment: TDP-43/cGAS/STING Therapeutic Hypotheses in Neurodegeneration
## Executive Summary
The source paper (Yu et al., Cell 2020) establishes a credible mechanistic link between T...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "STING Antagonists as ALS Therapeutics: Drug Repurposing",
"description": "Existing STING antagonists (H-151, SN-011, Compound 18) developed for a...